SARS-CoV-2: Vaccines in the pandemic era

Dan-Dan Li; Qi-Han Li

doi:10.1186/s40779-020-00296-y

Your Location：

Home >

Browse articles >

SARS-CoV-2: Vaccines in the pandemic era

REVIEW | Updated：2023-02-28

- SARS-CoV-2: Vaccines in the pandemic era
- SARS-CoV-2: Vaccines in the pandemic era
- 解放军医学杂志（英文版） 2021年8卷第2期页码：238-252
- Affiliations：
  
  Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, No. 935 Jiaoling Road, Kunming 650118, Yunnan, China
- Author bio：
  
  * liqihan@imbcams.com.cn
- Funds：
  
  the National Key R&D Program of China(2020YFC0849700);the Program of Chinese Academy of Medicine Science and the Major Science and Technology Special Projects of Yunnan Province
- DOI：10.1186/s40779-020-00296-y
  中图分类号：
- 纸质出版：2021-06
- Accepted：
Scan QR Code
SARS-CoV-2: Vaccines in the pandemic era[J]. 解放军医学杂志（英文版）, 2021,8(2):238-252.

Li et al.: SARS-CoV-2: vaccines in the pandemic era. Mil Med Res, 2021, 8: 1.
SARS-CoV-2: Vaccines in the pandemic era[J]. 解放军医学杂志（英文版）, 2021,8(2):238-252. DOI： 10.1186/s40779-020-00296-y.

Li et al.: SARS-CoV-2: vaccines in the pandemic era. Mil Med Res, 2021, 8: 1. DOI： 10.1186/s40779-020-00296-y.

摘要

Abstract

Coronavirus disease 2019 (COVID-19)

caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

has caused millions of infections and deaths worldwide since its emergence in December 2019. As there is little or no natural immunity in the human population or specific anti-COVID-19 drugs

researchers from the government

academia and industry are developing vaccines at an unprecedented speed to halt the pandemic. In this review

the results of animal experiments and clinical trials on several vaccine technical platforms are summarized

and several challenges are also discussed to further promote the development

evaluation and application of vaccines during the challenging situation of the global pandemic.

关键词

Keywords

references

International Monetary Fund . World economic outlook update, June 2020: A crisis like no other, an uncertain recovery 2020 . https://www.imf.org/en/Publications/WEO/Issues/2020/06/24/WEOUpdateJune2020 https://www.imf.org/en/Publications/WEO/Issues/2020/06/24/WEOUpdateJune2020 . Accessed 07 Sept2020 .

IMFBlog . The great lockdown: Worst economic downturn since the great depression . 2020 . https://blogs.imf.org/2020/04/14/the-great-lockdownworst-economic-downturn-since-the-great-depression/ https://blogs.imf.org/2020/04/14/the-great-lockdownworst-economic-downturn-since-the-great-depression/ . Accessed 10 Sept 2020 .

WHO . WHO coronavirus disease (COVID-19) dashboard . 2020 . https://covid19.who.int/ https://covid19.who.int/ . Accessed 14 Dec 2020 .

Oberfeld B , Achanta A , Carpenter K , Chen P , Gilette NM , Langat P , et al . Snapshot: COVID-19 . Cell . 2020 ; 181 ( 4 ): 954 .

de Wit E , van Doremalen N , Falzarano D , Munster VJ . SARS and MERS: recent insights into emerging coronaviruses . Nat Rev Microbiol . 2016 ; 14 ( 8 ): 523 - 34 .

Wu F , Zhao S , Yu B , Chen YM , Wang W , Song ZG , et al . A new coronavirus associated with human respiratory disease in China . Nature . 2020 ; 579 ( 7798 ): 265 - 9 .

Wu A , Peng Y , Huang B , Ding X , Wang X , Niu P , et al . Genome composition and divergence of the novel coronavirus (2019-nCOV) originating in China . Cell Host Microbe . 2020 ; 27 ( 3 ): 325 - 8 .

Zhu N , Zhang D , Wang W , Li X , Yang B , Song J , et al . A novel coronavirus from patients with pneumonia in China, 2019 . N Engl J Med . 2020 ; 382 ( 8 ): 727 - 33 .

Gallagher TM , Buchmeier MJ . Coronavirus spike proteins in viral entry and pathogenesis . Virology . 2001 ; 279 ( 2 ): 371 - 4 .

Neuman BW , Kiss G , Kunding AH , Bhella D , Baksh MF , Connelly S , et al . A structural analysis of m protein in coronavirus assembly and morphology . J Struct Biol . 2011 ; 174 ( 1 ): 11 - 22 .

DeDiego ML , Alvarez E , Almazan F , Rejas MT , Lamirande E , Roberts A , et al . A severe acute respiratory syndrome coronavirus that lacks the e gene is attenuated in vitro and in vivo . J Virol . 2007 ; 81 ( 4 ): 1701 - 13 .

Zhou P , Yang XL , Wang XG , Hu B , Zhang L , Zhang W , et al . A pneumonia outbreak associated with a new coronavirus of probable bat origin . Nature . 2020 ; 579 ( 7798 ): 270 - 3 .

Wan Y , Shang J , Graham R , Baric RS , Li F . Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus . J Virol . 2020 ; 94 ( 7 ): e00127 - 20 .

Du L , Yang Y , Zhou Y , Lu L , Li F , Jiang S . MERS-CoV spike protein: a key target for antivirals . Expert Opin Ther Targets . 2017 ; 21 ( 2 ): 131 - 43 .

Larocca RA , Abbink P , Peron JP , Zanotto PM , Iampietro MJ , Badamchi-Zadeh A , et al . Vaccine protection against Zika virus from Brazil . Nature . 2016 ; 536 ( 7617 ): 474 - 8 .

Dowd KA , Ko SY , Morabito KM , Yang ES , Pelc RS , DeMaso CR , et al . Rapid development of a DNA vaccine for Zika virus . Science . 2016 ; 354 ( 6309 ): 237 - 40 .

Kibuuka H , Berkowitz NM , Millard M , Enama ME , Tindikahwa A , Sekiziyivu AB , et al . Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial . Lancet . 2015 ; 385 ( 9977 ): 1545 - 54 .

Gaudinski MR , Houser KV , Morabito KM , Hu Z , Yamshchikov G , Rothwell RS , et al . Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials . Lancet . 2018 ; 391 ( 10120 ): 552 - 62 .

O'Callaghan KP , Blatz AM , Offit PA . Developing a SARS-CoV-2 vaccine at warp speed . JAMA . 2020 ; 324 ( 5 ): 437 - 8 .

Mulligan MJ , Lyke KE , Kitchin N , Absalon J , Gurtman A , Lockhart SP , et al . Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report . medRxiv . 2020 . https://doi.org/10.1101/2020.06.30.20142570 https://doi.org/10.1101/2020.06.30.20142570 .

Sahin U , Muik A , Derhovanessian E , Vogler I , Kranz LM , Vormehr M , et al . COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses . Nature . 2020 ; 586 ( 7830 ): 594 - 9 .

Walsh EE , Frenck R , Falsey AR , Kitchin N , Absalon J , Gurtman A , et al . RNAbased COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study . medRxiv . 2020 . https://doi.org/10.1101/2020.08.17.20176651 https://doi.org/10.1101/2020.08.17.20176651 .

Walsh EE , Frenck RW Jr , Falsey AR , Kitchin N , Absalon J , Gurtman A , et al . Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates . N Engl J Med . 2020 . https://doi.org/10.1056/NEJMoa2027906 https://doi.org/10.1056/NEJMoa2027906 .

Vogel AB , Kanevsky I , Che Y , Swanson KA , Muik A , Vormehr M , et al . A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates . bioRxiv . 2020 . https://doi.org/10.1101/2020.09.08.280818 https://doi.org/10.1101/2020.09.08.280818 .

Pfizer . A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals . 2020 . https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf 10 Nov 2020 https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf 10 Nov 2020 .

Pfizer . Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study . 2020 . https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechannounce-vaccine-candidate-against https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechannounce-vaccine-candidate-against . Accessed 10 Nov 2020 .

Jackson LA , Anderson EJ , Rouphael NG , Roberts PC , Makhene M , Coler RN , et al . An mRNA vaccine against SARS-CoV-2 - preliminary report . N Engl J Med . 2020 ; 383 ( 20 ): 1920 - 31 .

BusinessWire . Moderna to present new interim clinical data about mRNA vaccine against COVID-19 (mRNA-1273) at advisory committee on immunization practices (ACIP) meeting . 2020 . https://www.businesswire.com/news/home/20200826005466/en https://www.businesswire.com/news/home/20200826005466/en . Accessed 10 Nov 2020 .

Anderson EJ , Rouphael NG , Widge AT , Jackson LA , Roberts PC , Makhene M , et al . Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults . N Engl J Med . 2020 . https://doi.org/10.1056/NEJMoa2028436 https://doi.org/10.1056/NEJMoa2028436 .

Corbett KS , Edwards DK , Leist SR , Abiona OM , Boyoglu-Barnum S , Gillespie RA , et al . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness . Nature . 2020 ; 586 ( 7830 ): 567 - 71 .

Corbett KS , Flynn B , Foulds KE , Francica JR , Boyoglu-Barnum S , Werner AP , et al . Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates . N Engl J Med . 2020 ; 383 ( 16 ): 1544 - 55 .

Moderna . Cove study: Participate to make a world of difference . 2020 . https://www.modernatx.com/cove-study https://www.modernatx.com/cove-study . Accessed 10 Nov 2020 .

Zhang NN , Li XF , Deng YQ , Zhao H , Huang YJ , Yang G , et al . A thermostable mRNA vaccine against COVID-19 . Cell . 2020 ; 182 ( 5 ): 1271 - 83 .

Smith TRF , Patel A , Ramos S , Elwood D , Zhu X , Yan J , et al . Immunogenicity of a DNA vaccine candidate for COVID-19 . Nat Commun . 2020 ; 11 ( 1 ): 2601 .

Patel A , Walters J , Reuschel EL , Schultheis K , Parzych E , Gary EN , et al . Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model . bioRxiv . 2020 . https://doi.org/10.1101/2020.07.28.225649 https://doi.org/10.1101/2020.07.28.225649 .

Zhu FC , Li YH , Guan XH , Hou LH , Wang WJ , Li JX , et al . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial . Lancet . 2020 ; 395 ( 10240 ): 1845 - 54 .

Zhu FC , Guan XH , Li YH , Huang JY , Jiang T , Hou LH , et al . Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial . Lancet . 2020 ; 396 ( 10249 ): 479 - 88 .

Wu S , Zhong G , Zhang J , Shuai L , Zhang Z , Wen Z , et al . A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge . Nat Commun . 2020 ; 11 ( 1 ): 4081 .

Rice A , Verma M , Shin A , Zakin L , Sieling P , Tanaka S , et al . A next generation bivalent human ad5 COVID-19 vaccine delivering both spike and nucleocapsid antigens elicits th1 dominant CD4 + , CD8 + T-cell and neutralizing antibody responses . bioRxiv . 2020 . https://doi.org/10.1101/2020.07.29.227595 https://doi.org/10.1101/2020.07.29.227595 .

Mercado NB , Zahn R , Wegmann F , Loos C , Chandrashekar A , Yu J , et al . Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques . Nature . 2020 ; 586 ( 7830 ): 583 - 8 .

Bos R , Rutten L , van der Lubbe JEM , Bakkers MJG , Hardenberg G , Wegmann F , et al . Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses . bioRxiv . 2020 ; 5 : 91 .

Sadoff J , Le Gars M , Shukarev G , Heerwegh D , Truyers C , de Groot AM , et al . Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial . medRxiv . 2020 . https://doi.org/10.1101/2020.09.23.20199604 https://doi.org/10.1101/2020.09.23.20199604 .

Janssen Vaccines & Prevention B.V . A randomized, double-blind, placebocontrolled phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older . 2020 . https://www.jnj.com/coronavirus/COVID-19-phase-3-study-clinical-protocol https://www.jnj.com/coronavirus/COVID-19-phase-3-study-clinical-protocol . Accessed 10 Nov 2020 .

van Doremalen N , Lambe T , Spencer A , Belij-Rammerstorfer S , Purushotham JN , Port JR , et al . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques . Nature . 2020 ; 586 ( 7830 ): 578 - 82 .

Silva-Cayetano A , Foster WS , Innocentin S , Belij-Rammerstorfer S , Spencer AJ , Burton OT , et al . A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice . bioRxiv . 2020 . https://doi.org/10.1101/2020.10.27.357426 https://doi.org/10.1101/2020.10.27.357426 .

Folegatti PM , Ewer KJ , Aley PK , Angus B , Becker S , Belij-Rammerstorfer S , et al . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial . Lancet . 2020 ; 396 ( 10249 ): 467 - 78 .

AstraZeneca . A phase III randomized, double-blind, placebo-controlled multicenter study in adults to determine the safety, efficacy, and immunogenicity of AZD1222, a non-replicating ChAdOx1 vector vaccine, for the prevention of COVID-19 . 2020 . https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf . Accessed 10 Nov 2020 .

Logunov DY , Dolzhikova IV , Zubkova OV , Tukhvatullin AI , Shcheblyakov DV , Dzharullaeva AS , et al . Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia . Lancet . 2020 ; 396 ( 10255 ): 887 - 97 .

Keech C , Albert G , Cho I , Robertson A , Reed P , Neal S , et al . Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine . N Engl J Med . 2020 ; 383 ( 24 ): 2320 - 32 .

Tian JH , Patel N , Haupt R , Zhou H , Weston S , Hammond H , et al . SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice . bioRxiv . 2020 . https://doi.org/10.1101/2020.06.29.178509 https://doi.org/10.1101/2020.06.29.178509 .

Guebre-Xabier M , Patel N , Tian J-H , Zhou B , Maciejewski S , Lam K , et al . NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge . Vaccine . 2020 ; 38 ( 50 ): 7892 - 6 .

Bangaru S , Ozorowski G , Turner HL , Antanasijevic A , Huang D , Wang X , et al . Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate . Science . 2020 ; 370 ( 6520 ): 1089 - 94 .

OLIAN News . Russia’s second COVID-19 vaccine is expected to complete phase 2 clinical trials in September . 2020 . https://k.sina.com.cn/article_6716299795_190529a1300100zl2y.html https://k.sina.com.cn/article_6716299795_190529a1300100zl2y.html . Accessed 10 Nov 2020 .

KREMLIN . Meeting with members of the government . 2020 . http://kremlin.ru/events/president/news/64203 http://kremlin.ru/events/president/news/64203 . Accessed 10 Nov 2020 .

Xia S , Duan K , Zhang Y , Zhao D , Zhang H , Xie Z , et al . Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials . JAMA . 2020 ; 324 ( 10 ): 951 - 60 .

Wang H , Zhang Y , Huang B , Deng W , Quan Y , Wang W , et al . Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 . Cell . 2020 ; 182 ( 3 ): 713 - 21 .

Xia S , Zhang Y , Wang Y , Wang H , Yang Y , Gao GF , et al . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial . Lancet Infect Dis . 2020 . https://doi.org/10.1016/S1473-3099(20)30831-8 https://doi.org/10.1016/S1473-3099(20)30831-8 .

Gao Q , Bao L , Mao H , Wang L , Xu K , Yang M , et al . Rapid development of an inactivated vaccine for SARS-CoV-2 . bioRxiv . 2020 . https://doi.org/10.1101/2020.04.17.046375 https://doi.org/10.1101/2020.04.17.046375 .

Zhang YJ , Zeng G , Pan HX , Li CG , Kan B , Hu YL , et al . Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: Report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial . medRxiv . 2020 . https://doi.org/10.1101/2020.07.31.20161216 https://doi.org/10.1101/2020.07.31.20161216 .

Chen H , Xie Z , Long R , Fan S , Li H , He Z , et al . A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-CoV-2 infection . bioRxiv . 2020 . https://doi.org/10.1101/2020.08.04.235747 https://doi.org/10.1101/2020.08.04.235747 .

Pu J , Yu Q , Yin Z , Zhang Y , Li X , Li D , et al . An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine . medRxiv . 2020 . https://doi.org/10.1101/2020.09.27.20189548 https://doi.org/10.1101/2020.09.27.20189548 .

Hassan AO , Case JB , Winkler ES , Thackray LB , Kafai NM , Bailey AL , et al . A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies . Cell . 2020 ; 182 ( 3 ): 744 - 53 .

Seo SH , Jang Y . Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ace2 transgenic mice from SARS-CoV-2 infection . bioRxiv . 2020 . https://doi.org/10.1101/2020.08.04.235689 https://doi.org/10.1101/2020.08.04.235689 .

Su YCF , Anderson DE , Young BE , Linster M , Zhu F , Jayakumar J , et al . Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2 . mBio . 2020 ; 11 ( 4 ): e01610 - 20 .

Young BE , Fong SW , Chan YH , Mak TM , Ang LW , Anderson DE , et al . Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study . Lancet . 2020 ; 396 ( 10251 ): 603 - 11 .

Lau SY , Wang P , Mok BW , Zhang AJ , Chu H , Lee AC , et al . Attenuated SARSCoV-2 variants with deletions at the S1/S2 junction . Emerg Microbes Infect . 2020 ; 9 ( 1 ): 837 - 42 .

Wang P , Lau SY , Deng S , Chen P , Mok BWY , Zhang AJ , et al . Pathogenicity, immunogenicity, and protective ability of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein . bioRxiv . 2020 . https://doi.org/10.1101/2020.08.24.264192 https://doi.org/10.1101/2020.08.24.264192 .

Dai L , Zheng T , Xu K , Han Y , Xu L , Huang E , et al . A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS . Cell . 2020 ; 182 ( 3 ): 722 - 33 .

Mitroulis I , Ruppova K , Wang B , Chen LS , Grzybek M , Grinenko T , et al . Modulation of myelopoiesis progenitors is an integral component of trained immunity . Cell . 2018 ; 172 ( 1–2 ): 147 - 61 .

Christ A , Gunther P , Lauterbach MAR , Duewell P , Biswas D , Pelka K , et al . Western diet triggers NLRP3-dependent innate immune reprogramming . Cell . 2018 ; 172 ( 1–2 ): 162 - 75 .

Kaufmann E , Sanz J , Dunn JL , Khan N , Mendonca LE , Pacis A , et al . BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis . Cell . 2018 ; 172 ( 1–2 ): 176 - 90 .

Arts RJW , Moorlag S , Novakovic B , Li Y , Wang SY , Oosting M , et al . BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity . Cell Host Microbe . 2018 ; 23 ( 1 ): 89 - 100 .

Sala G , Chakraborti R , Ota A , Miyakawa T . Association of BCG vaccination policy and tuberculosis burden with incidence and mortality of COVID-19 . medRxiv . 2020 . https://doi.org/10.1101/2020.03.30.20048165 https://doi.org/10.1101/2020.03.30.20048165 .

Shet A , Ray D , Malavige N , Santosham M , Bar-Zeev N . Differential COVID-19-attributable mortality and BCG vaccine use in countries . medRxiv . 2020 . https://doi.org/10.1101/2020.04.01.20049478 https://doi.org/10.1101/2020.04.01.20049478 .

Miller A , Reandelar MJ , Fasciglione K , Roumenova V , Li Y , Otazu GH . Correlation between universal BCG vaccination policy and reduced mortality for COVID-19 . medRxiv . 2020 . https://doi.org/10.1101/2020.03.24.20042937 https://doi.org/10.1101/2020.03.24.20042937 .

Berg MK , Yu Q , Salvador CE , Melani I , Kitayama S . Mandated bacillus calmette-guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19 . medRxiv . 2020 . https://doi.org/10.1101/2020.04.05.20054163 https://doi.org/10.1101/2020.04.05.20054163 .

Curtis N , Sparrow A , Ghebreyesus TA , Netea MG . Considering BCG vaccination to reduce the impact of COVID-19 . Lancet . 2020 ; 395 ( 10236 ): 1545 - 6 .

WHO . DRAFT landscape of COVID-19 candidate vaccines . 2020 . https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-191cf012d2866d4102b9430ef02369d152.pdf https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-191cf012d2866d4102b9430ef02369d152.pdf . Accessed 10 Nov 2020 .

Israelow B , Song E , Mao T , Lu P , Meir A , Liu F , et al . Mouse model of SARSCoV-2 reveals inflammatory role of type I interferon signaling . J Exp Med . 2020 ; 217 ( 12 ): e20201241 .

Sun J , Zhuang Z , Zheng J , Li K , Wong RL , Liu D , et al . Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment . Cell . 2020 ; 182 ( 3 ): 734 - 43 .

Winkler ES , Bailey AL , Kafai NM , Nair S , McCune BT , Yu J , et al . SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function . Nat Immunol . 2020 ; 21 ( 11 ): 1327 - 35 .

Dinnon KH 3rd , Leist SR , Schafer A , Edwards CE , Martinez DR , Montgomery SA , et al . A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures . Nature . 2020 ; 586 ( 7830 ): 560 - 6 .

Leist SR , Dinnon KH 3rd , Schafer A , Tse LV , Okuda K , Hou YJ , et al . A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice . Cell . 2020 ; 183 ( 4 ): 1070 - 85 .

Tostanoski LH , Wegmann F , Martinot AJ , Loos C , McMahan K , Mercado NB , et al . Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters . Nat Med . 2020 ; 26 ( 11 ): 1694 - 700 .

Netland J , Meyerholz DK , Moore S , Cassell M , Perlman S . Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2 . J Virol . 2008 ; 82 ( 15 ): 7264 - 75 .

Deng W , Bao L , Liu J , Xiao C , Liu J , Xue J , et al . Primary exposure to SARSCoV-2 protects against reinfection in rhesus macaques . Science . 2020 ; 369 ( 6505 ): 818 - 23 .

Deng W , Bao L , Gao H , Xiang Z , Qu Y , Song Z , et al . Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques . Nat Commun . 2020 ; 11 ( 1 ): 4400 .

Iwasaki A . What reinfections mean for COVID-19 . Lancet Infect Dis . 2020 . https://doi.org/10.1016/S1473-3099(20)30783-0 https://doi.org/10.1016/S1473-3099(20)30783-0 .

Schäfer A , Muecksch F , Lorenzi JCC , Leist SR , Cipolla M , Bournazos S , et al . Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo . bioRxiv . 2020 . https://doi.org/10.1101/2020.09.15.298067 https://doi.org/10.1101/2020.09.15.298067 .

Seow J , Graham C , Merrick B , Acors S , Pickering S , Steel KJA , et al . Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans . Nat Microbiol . 2020 ; 5 ( 12 ): 1598 - 607 .

Korber B , Fischer WM , Gnanakaran S , Yoon H , Theiler J , Abfalterer W , et al . Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus . Cell . 2020 ; 182 ( 4 ): 812 - 27 .

Plante JA , Liu Y , Liu J , Xia H , Johnson BA , Lokugamage KG , et al . Spike mutation D614G alters SARS-CoV-2 fitness . Nature . 2020 . https://doi.org/10.1038/s41586-020-2895-3 https://doi.org/10.1038/s41586-020-2895-3 .

Zhang L , Jackson CB , Mou H , Ojha A , Rangarajan ES , Izard T , et al . The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity . bioRxiv . 2020 . https://doi.org/10.1101/2020.06.12.148726 https://doi.org/10.1101/2020.06.12.148726 .

Keech C , Albert G , Reed P , Neal S , Plested JS , Zhu M , et al . First-in-human trial of a SARSCoV2 recombinant spike protein nanoparticle vaccine.medRxiv . 2020 . https://doi.org/10.1101/2020.08.05.20168435 https://doi.org/10.1101/2020.08.05.20168435 .

Ke Z , Oton J , Qu K , Cortese M , Zila V , McKeane L , et al . Structures and distributions of SARS-CoV-2 spike proteins on intact virions . Nature . 2020 ; 588 ( 7838 ): 498 - 502 . https://doi.org/10.1038/s41586-020-2665-2 https://doi.org/10.1038/s41586-020-2665-2 .

Deming D , Sheahan T , Heise M , Yount B , Davis N , Sims A , et al . Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants . PLoS Med . 2006 ; 3 ( 12 ): e525 .

Liu L , Wei Q , Lin Q , Fang J , Wang H , Kwok H , et al . Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection . JCI Insight . 2019 ; 4 ( 4 ): e123158 .

Yang ZY , Werner HC , Kong WP , Leung K , Traggiai E , Lanzavecchia A , et al . Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses . Proc Natl Acad Sci U S A . 2005 ; 102 ( 3 ): 797 - 801 .

Zhang L , Zhang F , Yu W , He T , Yu J , Yi CE , et al . Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals . J Med Virol . 2006 ; 78 ( 1 ): 1 - 8 .

Wu F , Yan R , Liu M , Liu Z , Wang Y , Luan D , et al . Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: Studies based on cellular and structural biology analysis . medRxiv . 2020 . https://doi.org/10.1101/2020.10.08.20209114 https://doi.org/10.1101/2020.10.08.20209114 .

Quinlan BD , Mou H , Zhang L , Guo Y , He W , Ojha A , et al . The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement . bioRxiv . 2020 . doi: https://doi.org/10.1101/2020.04.10.036418 https://doi.org/10.1101/2020.04.10.036418 .

Gao Q , Bao L , Mao H , Wang L , Xu K , Yang M , et al . Development of an inactivated vaccine candidate for SARS-CoV-2 . Science . 2020 ; 369 ( 6499 ): 77 - 81 .

Rogers TF , Zhao F , Huang D , Beutler N , Burns A , He WT , et al . Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model . Science . 2020 ; 369 ( 6506 ): 956 - 63 .

Cleary SJ , Pitchford SC , Amison RT , Carrington R , Robaina Cabrera CL , Magnen M , et al . Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology . Br J Pharmacol . 2020 ; 177 ( 21 ): 4851 - 65 .

Joyner MJ , Wright RS , Fairweather D , Senefeld JW , Bruno KA , Klassen SA , et al . Early safety indicators of COVID-19 convalescent plasma in 5000 patients . J Clin Invest . 2020 ; 130 ( 9 ): 4791 - 7 .

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Advances in the design and development of SARS-CoV-2 vaccines

A cross-sectional study of olfactory and taste disorders among COVID-19 patients in China

Common mtDNA variations at C5178a and A249d/T6392C/G10310A decrease the risk of severe COVID-19 in a Han Chinese population from Central China

Development of rapid advice guideline and standard and continuous updating guideline: experiences and practice

Early stage nonclinical pulmonary disorder in COVID-19 may present asymptomatic and fuel the contagion